ReviewJournal for immunotherapy of cancer2022
Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?
Review in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.Molecular cancer · 2024Trial
- Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics.Cancer medicine · 2026Review
- Value of [European journal of nuclear medicine and molecular imaging · 2026Article
- Machine learning-based models for tumor mutation burden prediction in gastrointestinal cancers: a systematic review and meta-analysis.Discover oncology · 2026Review
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- Article
- Clinical-radiomics nomogram integrating lymph node radiomic features to predict immunotherapy response in advanced biliary tract cancers.Journal for immunotherapy of cancer · 2025Article
- Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.Cancer metastasis reviews · 2025Review
- Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.Journal for immunotherapy of cancer · 2025Article
- From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Heterogeneous intratumor irradiation: a new partner for immunotherapy.Oncoimmunology · 2024Article
- Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis.Annals of nuclear medicine · 2024Article
- A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?NPJ precision oncology · 2024Review
- Principles of risk assessment in colon cancer: immunity is key.Oncoimmunology · 2024Review
- Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.Journal for immunotherapy of cancer · 2023Article
- A Radiomics Approach to Identify Immunologically Active Tumor in Patients with Head and Neck Squamous Cell Carcinomas.Cancers · 2023Article
- Artificial Intelligence and Radiomics: Clinical Applications for Patients with Advanced Melanoma Treated with Immunotherapy.Diagnostics (Basel, Switzerland) · 2023Review
- Radiogenomics: a key component of precision cancer medicine.British journal of cancer · 2023Review
- A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.European radiology · 2023Article
- PET-based radiomics visualizes tumor-infiltrating CD8 T cell exhaustion to optimize radiotherapy/immunotherapy combination in mouse models of lung cancer.Biomarker research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Strong rationale and a growing number of preclinical and clinical studies support combining radiotherapy and immunotherapy to improve patient outcomes. However, several critical questions remain, such as the identification of patients who will benefit from immunotherapy and the identification of the best modalities of treatment to optimize patient response. Imaging biomarkers and radiomics have recently emerged as promising tools for the non-invasive assessment of the whole disease of the patient, allowing comprehensive analysis of the tumor microenvironment, the spatial heterogeneity of the disease and its temporal changes. This review presents the potential applications of medical imaging and the challenges to address, in order to help clinicians choose the optimal modalities of both radiotherapy and immunotherapy, to predict patient's outcomes and to assess response to these promising combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.